I’ve
written about ERAP1 at the EULAR 2014 Meeting in Paris, where I had gotten
interested in two abstracts and guessed [1]: “My guess is that it isn’t the
last we hear about ERAP1 in ankylosing spondylitis.” Let’s have a look at ERAP1
at the 2017 EULAR Annual Meeting in Madrid.
A. de
Koning and colleagues presented [2]: “ERAP1 IS A SUSCEPTIBILITY FACTOR FOR
EARLY AXIAL SPONDYLOARTHRITIS MEETING THE ASAS CLASSIFICATION CRITERIA: RESULTS
FROM THE DESIR AND SPACE COHORTS”. Conclusions: “ERAP1 rs30187 is a genetic
risk factor for early axSpA. To our knowledge this is the first report of
genetic risk factor research in early axSpA [axial spondyloarthritis] patients
meeting the ASAS [Assessment of SpondyloArthritis] criteria [3]. Larger cohorts
are needed to study additional AS [ankylosing spondylitis] risk factors.”
J. Londono
and colleagues looked at [4]: “THU0005 ERAP POLYMORPHISMS AND ITS ASSOCIATION
WITH HLA-B15 AND HLA-B27 POSITIVE SPONDYLARTHRITIS PATIENTS”. “Since 1973, the
association of HLA-B27 and spondyloarthritis (SpA) is well known, however in
Colombian population it is present in only 40% of patients and HLA-B15 is
present almost in 25%.” Conclusions:” In the group of patients analysed, a
statistically significant association was found between patients with SpA
HLA-B15 positive and the haplotype TGT of ERAP2. Also HLA-B27 positive SpA
patients were associated with haplotype TGC and CAT of ERAP2 with statistical
significance”. Interestingly there were no associations between ERAP1
haplotypes and HLA-B15 or B27 in this Colombian cohort.
ERAP1 and
also ERAP2 haplotypes open new horizons for research in ankylosing spondylitis
and maybe we’ll use these genetic factors later in a probability index to calculate the risk for
forms of spondyloarthritis.
Links and
References:
[2] DOI:
10.1136/annrheumdis-2017-eular.5955
[4] DOI:
10.1136/annrheumdis-2017-eular.5659
.
No comments:
Post a Comment